Vaccine composition comprising recombinant nipah virus protein

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
A recombinant protein vaccine for Nipah and Hendra viruses, derived from G and F proteins of specific strains, addresses the lack of effective treatments by inducing a strong immune response and offering diagnostic solutions.

WO2026135005A1 Publication Date: 2026-06-25KOREA NAT INST OF HEALTH

0 Cites 0 Cited by

Patent Information

Application Number: PCT/KR2025/021401
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-12-20
Filing Date: 2025-12-11
Publication Date: 2026-06-25

Application Information

Patent Timeline

20 Dec 2024

Priority

11 Dec 2025

Application

PCT/KR2025/021401

25 Jun 2026

Publication

WO2026135005A1

IPC: A61K39/155; A61P31/14; A61P37/02; C07K14/005; G01N33/569; A61K39/00

CPC: A61K39/00; A61K39/155; A61P31/14; A61P37/02; C07K14/005; G01N33/569

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Virus peptides Antivirals

Technology Topics

Adjuvant F protein

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

There are currently no effective vaccines or treatments for preventing or treating Nipah and Hendra virus infections, which are caused by henipaviruses that express G and F proteins for cell fusion.

Method used

A vaccine composition comprising recombinant proteins derived from the G and F proteins of Nipah and Hendra viruses, specifically the Bangladesh and Malaysia strains, is developed, which includes an adjuvant to enhance immunogenicity and induce a cell-mediated immune response.

Benefits of technology

The recombinant protein vaccine demonstrates excellent immunogenicity and induces a robust immune response, providing protection against Nipah and Hendra viruses, as well as diagnostic capabilities for infection detection.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention relates to a vaccine composition comprising a recombinant Nipah virus protein. The vaccine composition according to the present invention not only exhibits excellent immunogenicity against both the G protein and the F protein of Nipah virus, but also exhibits immunogenicity against the G protein and the F protein of Hendra virus, and thus can be used as a universal vaccine against Henipavirus. In addition, the vaccine composition has the characteristic of inducing cell-mediated immune responses, and therefore can be provided as a formulation for enhancing specific immune responses to an administered drug such as an adjuvant or a vaccine.

Need to check novelty before this filing date? Find Prior Art